{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:16:08Z","timestamp":1793754968432,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13561-016-0124-4","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T04:34:22Z","timestamp":1475123662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany \u2013 are additional data requirements by the Federal Joint Committee justified?"],"prefix":"10.1186","volume":"6","author":[{"given":"J\u00f6rg","family":"Ruof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Staab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalabos-Markos","family":"Dintsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Schr\u00f6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich Wilhelm","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"124_CR1","unstructured":"Food and Drug Administration. Postmarketing Studies and Clinical Trials - Implementation of section 505(o)(3) of the Federal Court Food, Drug and Cosmetic Act. 2011. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM172001.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR2","unstructured":"European Medicines Agency. European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/10\/WC500003981.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR3","unstructured":"Bundesministerium f\u00fcr Gesundheit. [AM-NutzenV]. 2010. \n                    http:\/\/www.gesetze-im-internet.de\/bundesrecht\/am-nutzenv\/gesamt.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR4","unstructured":"Deutscher Bundestag. [Sozialgesetzbuch (SGB) F\u00fcnftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477, letzte \u00c4nderung durch Artikel 3 des Gesetzes vom 20. Dezember 2012 (BGBI. I S. 2781))]. 1988. \n                    http:\/\/www.gesetze-im-internet.de\/bundesrecht\/sgb_5\/gesamt.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR5","unstructured":"Gemeinsamer Bundesausschuss. Chapter 5: Assessment of the benefits of pharmaceuticals according to \u00a735a SGB V. 2012. \n                    http:\/\/www.english.g-ba.de\/downloads\/17-98-3042\/2011-05-18_5%20Kapitel%20VerfO%20Englisch.pdf\n                    \n                  . Accessed 18 Aug 2016"},{"issue":"2\u20133","key":"124_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.healthpol.2013.12.008","volume":"116","author":"H H\u00f6rn","year":"2014","unstructured":"H\u00f6rn H, Nink K, McGauran N, Wieseler B. Early benefit assessment of new drugs in Germany - Results from 2011 to 2012. Health Policy. 2014;116(2\u20133):147\u201353.","journal-title":"Health Policy"},{"issue":"6","key":"124_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10198-013-0495-y","volume":"15","author":"J Ruof","year":"2014","unstructured":"Ruof J, Schwartz FW, Schulenburg JM, Dintsios CM. Early benefit assessment (EBA) in Germany: analysing decisions 18\u00a0months after introducing the new AMNOG legislation. Eur J Health Econ. 2014;15(6):577\u201389.","journal-title":"Eur J Health Econ"},{"key":"124_CR8","unstructured":"Gemeinsamer Bundesausschuss. Overview of products [\u00dcbersicht der Wirkstoffe]. 2016. \n                    http:\/\/www.g-ba.de\/informationen\/nutzenbewertung\/\n                    \n                  . Accessed 18 Aug 2016"},{"key":"124_CR9","unstructured":"European Medicines Agency. European public assessment reports. 2016. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR10","unstructured":"Bundessozialgericht. [Urt. v. 31.05.2006, Az.: B 6 KA 13\/05 R]. 2006. \n                    http:\/\/www.aok-business.de\/fachthemen\/pro-personalrecht-online\/datenbank\/urteile-ansicht\/poc\/docid\/2505916\/\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR11","unstructured":"Gemeinsamer Bundesausschuss. [Stellungnahme des G-BA zum Fraktionsentwurf von CDU\/CSU und FDP zu einem Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz - AMNOG; BT\/Drucks. 17\/2413) - Korrigierte, um Punkt 8. auf Seite 7 erweiterte Fassung -]. 2010. \n                    https:\/\/www.g-ba.de\/downloads\/17-98-2896\/Stellungnahme%20G-BA%20zum%20AMNOG_Anh%C3%B6rung%2029-09-2010.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR12","unstructured":"Bundessozialgericht. [Urt. v. 01.03.2011, Az.: B 1 KR 7\/10 R]. 2011. \n                    https:\/\/openjur.de\/u\/169319.html\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR13","unstructured":"Gr\u00fcne M. [\u201eBedeutung der Zulassung f\u00fcr die Nutzenbewertung\u201c- Stellenwert des Zulassungsstatus bei G-BA- Entscheidungen]. 2013. \n                    https:\/\/www.iqwig.de\/download\/13-06-21_IQWiG_im_Dialog_Maximilian_Gruene_Bedeutung_der_Zulassung_Nutzenbewertung_Stellenwert_des_Zulassungsstatus_bei_G-BA-Entscheidungen.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"issue":"1","key":"124_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2191-1991-4-2","volume":"4","author":"I Dabisch","year":"2014","unstructured":"Dabisch I, Dethling J, Dintsios CM, Drechsler M, Kalanovic D, Kaskel P, et al. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Econ Rev. 2014;4(1):2\u20139.","journal-title":"Health Econ Rev"},{"issue":"8\u20139","key":"124_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.zefq.2014.06.015","volume":"108","author":"T Kvitkina","year":"2014","unstructured":"Kvitkina T, ten Haaf A, Reken S, McGauran N, Wieseler B. Patient-relevant outcomes and surrogates in the early benefitassessment of drugs: first experiences [Patientenrelevante Endpunkte und Surrogate in der fr\u00fchen Nutzenbewertung von Arzneimitteln: erste Erfahrungen]. Z Evid Fortbild Qual Gesundhwesen. 2014;108(8\u20139):528\u201338.","journal-title":"Z Evid Fortbild Qual Gesundhwesen"},{"issue":"2","key":"124_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.healthpol.2014.08.004","volume":"118","author":"J Ruof","year":"2014","unstructured":"Ruof J, Knoerzer D, Duenne AA, Dintsios CM, Staab T, Schwartz FW. Analysis of Endpoints Used in Marketing Authorisations versus Value Assessments of Oncology Medicines in Germany. Health Policy. 2014;118(2):242\u201354.","journal-title":"Health Policy"},{"key":"124_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/bcp.13023","volume":"82","author":"G Tafuri","year":"2016","unstructured":"Tafuri G, Pagnini M, Moseley J, Massari M, Petavy F, Behring A, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82:965\u201373.","journal-title":"Br J Clin Pharmacol"},{"key":"124_CR18","doi-asserted-by":"crossref","unstructured":"Ecker T, Fink C, Puetz C. Assessing medicinal products with limited evidence in Germany \u2013 current experience. Value Health. 2015;18(7):A551. (abstract and poster PHP213 presented at ISPOR 2015, Milan, Italy).","DOI":"10.1016\/j.jval.2015.09.1768"},{"key":"124_CR19","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. [Les \u00e9tudes post-inscription sur les technologies de sant\u00e9 (m\u00e9dicaments, dispositifs m\u00e9dicaux et actes) - Principes et m\u00e9thodes]. 2011. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2012-01\/etudes_post_inscription_technologies_sante.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR20","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General Methods 4.2. 2015. \n                    https:\/\/www.iqwig.de\/download\/IQWiG_General_Methods_Version_%204-2.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"issue":"1","key":"124_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13561-014-0012-8","volume":"4","author":"V Ivandic","year":"2014","unstructured":"Ivandic V. Requirements for benefit assessment in Germany and England - overview and comparison. Health Econ Rev. 2014;4(1):12.","journal-title":"Health Econ Rev"},{"key":"124_CR22","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2013. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/1-foreword\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR23","unstructured":"[Rahmenvereinbarung nach \u00a7 130b Abs. 9 SGB V]. 2015. \n                    https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/arzneimittel\/rahmenvertraege\/pharmazeutische_unternehmer\/Arzneimittel_RV_nach_130b_Abs_9_SGB-V_20150826.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR24","unstructured":"Bundesministerium f\u00fcr Gesundheit. [Das Gesetz zur Neuordnung des Arzneimittelmarktes (AMNOG)]. \n                    http:\/\/www.bmg.bund.de\/krankenversicherung\/arzneimittelversorgung\/amnog\/amnog.html\n                    \n                  . Accessed 18 Aug 2016."},{"issue":"1","key":"124_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13561-014-0031-5","volume":"4","author":"A Lebioda","year":"2014","unstructured":"Lebioda A, Gasche D, Dippel FW, Theobald K, Plantor S. Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland. Health Econ Rev. 2014;4(1):31.","journal-title":"Health Econ Rev"},{"key":"124_CR26","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie. [Politischer Streit auf dem R\u00fccken der Krebspatienten \u2013 Marktr\u00fccknahme von Regorafenib]. 2016. \n                    https:\/\/www.dgho-service.de\/dgho\/informationen\/presse\/pressemitteilungen\/politischer-streit-auf-dem-ruecken-der-krebspatienten-2013-marktruecknahme-von-regorafenib\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR27","doi-asserted-by":"publisher","DOI":"10.5771\/9783845271521","volume-title":"AMNOG auf dem \u00f6konomischen Pr\u00fcfstand - Funktionsweise, Ergebnisse und Reformbedarf der Preisregulierung f\u00fcr neue Arzneimittel in Deutschland","author":"D Cassel","year":"2015","unstructured":"Cassel D, Ulrich V. AMNOG auf dem \u00f6konomischen Pr\u00fcfstand - Funktionsweise, Ergebnisse und Reformbedarf der Preisregulierung f\u00fcr neue Arzneimittel in Deutschland. 1st ed. Baden-Baden: Nomos Verlagsgesellschaft; 2015.","edition":"1"},{"key":"124_CR28","unstructured":"Pharma Fakten. [Zulassung und Nutzenbewertung - Bundesinstitute und G-BA wollen gemeinsam Kriterien verbessern]. 2016. \n                    https:\/\/www.pharma-fakten.de\/news\/details\/376-zulassung-und-nutzenbewertung-bundesinstitute-und-g-ba-wollen-gemeinsam-kriterien-verbessern\/\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR29","unstructured":"Gemeinsamer Bundesausschuss, Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, Paul-Ehrlich-Institut. Strukturierte Zusammenarbeit zwischen dem Gemeinsamen Bundesausschuss, dem Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte und dem Paul-Ehrlich-Institut. 2016. \n                    http:\/\/www.bmg.bund.de\/fileadmin\/dateien\/Downloads\/P\/Pharmadialog\/Vereinbarung_G-BA-BOB_2016-04-12.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"key":"124_CR30","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. [Stellungnahme der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zum Verfahren der Fr\u00fchen Nutzenbewertung von Arzneimitteln nach \u00a735a SGBV und aufgrund des Arzneimittelmarktneuordnungsgesetzes (AMNOG) von 2010 vom 24.02.2015]. 2015. \n                    http:\/\/www.awmf.org\/fileadmin\/user_upload\/Stellungnahmen\/Medizinische_Versorgung\/AWMF-Stellungnahme_AMNOG_2015-02-24.pdf\n                    \n                  . Accessed 18 Aug 2016."},{"issue":"1","key":"124_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/bimj.201300256","volume":"58","author":"F Leverkus","year":"2016","unstructured":"Leverkus F, Chuang-Stein C. Implementation of AMNOG: An industry perspective. Biom J. 2016;58(1):76\u201388.","journal-title":"Biom J"},{"issue":"3","key":"124_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00103-014-2108-z","volume":"58","author":"P Beinlich","year":"2015","unstructured":"Beinlich P, Muller-Berghaus J, Sudhop T, Vieths S, Broich K. Interplay between marketing authorization and early benefit assessment of drugs. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2015;58(3):227\u201331.","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"issue":"3","key":"124_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000446537","volume":"19","author":"L Leyens","year":"2016","unstructured":"Leyens L, Brand A. Early patient access to medicines: health technology assessment bodies need to catch Up with New marketing authorization methods. Public Health Genomics. 2016;19(3):187\u201391.","journal-title":"Public Health Genomics"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-016-0124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13561-016-0124-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-016-0124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T14:03:42Z","timestamp":1561385022000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-016-0124-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["124"],"URL":"https:\/\/doi.org\/10.1186\/s13561-016-0124-4","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]},"assertion":[{"value":"2 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"46"}}